FOR PUBLIC RELEASE
NZX Limited
Wellington

Monday, 3 May 2021

GMP certification delayed due to overseas testing hold up.

Rua Bioscience (NZX:RUA) announces a delay in its Good Manufacturing Practice (GMP) certification as a result of hold ups in testing overseas.

The company commenced the multi-stage GMP certification process in November and had expected to achieve certification by late April, reiterating that view in its Half Year Results announcement on 26 February 2021. The delay is related to a validation test that required the dispatch of samples to Melbourne and Canada – with product held up in international Customs now impacting testing timeframes.

The delay is unexpected and outside of the company's control but unlikely to impact Rua's longer term goal of dispatching its first export consignment to Germany by the end of the 2021 calendar year (under its sales agreement with Nimbus Health).

Rua Bioscience understands it is the first medicinal cannabis company in New Zealand to be audited by Medsafe for GMP certification. Rua has otherwise been pleased with its navigation of the process.

ENDS

For more information, please visit www.ruabio.com, or contact:
Kerry Donovan
Communications Manager
Rua Bioscience
M 021 128 7689
kerry.donovan@ruabio.com

About Rua Bioscience
Rua Bioscience is a New Zealand pharmaceutical company aiming to be a leading producer of cannabinoid derived medicines for both export and local markets. Rua has been an early mover in the sector and was the first private company in New Zealand to receive a licence to cultivate cannabis for research purposes. Founded in 2017 in Ruatorea as a subsidiary of charitable company Hikurangi Enterprises Limited, Rua is underpinned by its mission to heal the people and heal the land. It is committed to New Zealand's Te Tairāwhiti (East Coast) region and its connection with its local community. The company has completed facilities for cultivation and manufacturing. www.ruabio.com

About GMP
GMP is a globally recognised set of minimum standards which describe the systems that manufacturers of medicines are required to have in place to ensure their products are consistently safe, effective and of acceptable quality. It is the production standard required for pharmaceutical grade products in most jurisdictions where medicinal cannabis is legal including the EU, UK, Australia and New Zealand. This certification is provided by Medsafe. and is required before commencing commercial production.